


P


*


P

P

Р







B

С

Figure 1 IFN γ , CXCL9, CXCL10 and Granzyme B are highly expressed in the skin lesion and plasma of vitiligo patients compare to healthy controls. **A.** Cytokine panel expression of paired lesion and non-lesion skin blister interstitial fluid and plasma analyte in vitiligo patients and healthy controls. **B.** Relative fold change cytokine panel in skin blisters interstitial fluid analyte in lesion and non-lesion skin of vitiligo patients compare to healthy controls. **C.** Relative fold change of cytokine panel in plasma analyte of vitiligo patients compare to healthy controls. (V:Vitiligo, L: lesion, NL: non-lesion; * p<0.05, ** p<0.01,*** p<0.001; ns: non-significant)




Figure 2. Pearson correlation analysis of IFN γ , CXCL9, CXCL10 and GzmB expression in skin blister interstitial fluid and plasma analyte in vitiligo patients. Plasma IFN γ , CXCL9 and CXCL10 expression is positively correlated with the skin lesion IFN γ expression. Plasma Granzyme B is correlated with skin lesion GzmB, CXCL9 and CXCL10. (* p<0.05, L: lesion, NL:non-lesion, P:plasma)






Figure 3. IFN γ and CXCL10 are correlated with disease activity, whereas CXCL9 is associated with disease severity in vitiligo patients. **A.** Disease activity: IFN γ , CXCL9, CXCL10, and GzmB in active and stable vitiligo and healthy control. **B.** ROC curve for disease activity in IFN γ and CXCL10, negative data of CXCL9 and GzmB not shown. **C.** Disease severity: IFN γ , CXCL9, CXCL10, and GzmB in VES <5 and VES >5 vitiligo patients. **D.** ROC curve for disease severity in CXCL9, negative data of IFN γ , CXCL10 and GzmB not shown (* p<0.05, ** p<0.01,*** p<0.001)



В.

Figure 4. A decrease in IFN- γ expression level before and six months after treatment correlates with good treatment response. **A.** Cytokine expression of IFN- γ , CXCL9, CXCL10, and GzmB at the initial visit. **B.** Difference in IFN- γ , CXCL9, CXCL10, and GzmB expression before and six months after treatment. (* p<0.05, ** p<0.01,*** p<0.001)



Supplement Fig 1. Patient collection flow chart.